At a glance
ClinicalIndex Comparison Record- ✓Age 18-75 years
- ✓Negative urine drug screen for illicit substances including cannabis
- ✓Medically cleared to take study medications
- ✓Not pregnant or breast feeding
- ✕Meets DSM-5 criteria for alcohol or substance use disorder
- ✕Currently taking opioids for pain
- ✕Previous adverse reaction to a cannabinoid product
- ✕Currently prescribed and taking stimulants or benzodiazepines
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Using Dronabinol to Enhance the Analgesic Effect of Hydromorphone in Humans
In Brief
A Phase 2 clinical trial evaluating Within-subject test of blinded study medications for Pain and 2 related conditions. Completed, enrolled 29 participants across 1 site.
Detailed Summary
This is a single-group, within-subject, double-blind, double-dummy, placebo and active-controlled study evaluated whether the FDA-approved cannabinoid dronabinol (Marinol) would enhance analgesia, subjective reports, and cognitive performance when compared to the FDA-approved opioid hydromorphone (Dilaudid).
Study Details
Timeline
Interventions
Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.